MetaVia Reports Third Quarter 2026 Financial Results and Provides Corporate Update

MetaVia posts positive early clinical data but faces rising losses and long timelines.

What the company is saying

MetaVia highlights positive interim Phase 1 Part 3B results for DA-1726, reporting a 68.1% placebo-adjusted reduction in liver fat and 13.5% placebo-adjusted weight loss after 16 weeks, with all five participants with baseline steatosis achieving MRI-PDFF below 5%. The company emphasizes statistically significant reductions in uric acid and adipose tissue, presenting these as evidence of DA-1726's potential for treating MetALD and ALD. Management frames these findings as a foundation for a planned 48-week Phase 2 study in up to 150 subjects, targeted for the second half of 2027, and positions the recent appointment of Sarah Browne, M.D., as Chief Medical Officer as strengthening clinical leadership. The narrative also includes progress on vanoglipel, with a Phase 2a proof-of-concept study in MASH targeted for the first half of 2027. Financial commentary attributes increased R&D and G&A expenses primarily to DA-1726 development, higher consulting, legal, and professional fees, and increased employee compensation. The tone is confident and forward-looking, but the company is clear that key clinical milestones and full data are still months or years away.

What the data suggests

The disclosed figures show MetaVia's operating losses are widening, with a net loss of $4.6 million ($0.69 per share) for Q3 2026, up from $3.4 million ($1.52 per share) in Q3 2025, and a nine-month net loss of $13.8 million ($2.36 per share) versus $11.0 million ($6.93 per share) the prior year. R&D expenses rose to $2.6 million for Q3 2026 (from $1.9 million), and to $8.2 million for the nine months (from $6.6 million), driven mainly by DA-1726 development. G&A expenses increased to $2.1 million for the quarter (from $1.6 million) and $5.9 million for the nine months (from $5.1 million), with higher consulting, legal, and tax costs. Cash and cash equivalents declined to $8.8 million as of September 30, 2026, from $10.3 million at year-end 2025. Interim clinical data for DA-1726 are promising but based on a very small sample (n=5 for key endpoints), and the company has not yet reported full Phase 1 results. All forward milestones, including the start of Phase 2 for DA-1726 and Phase 2a for vanoglipel, are at least several months away. The financial trajectory is negative, and the company remains pre-revenue.

Analysis

The announcement presents positive interim Phase 1 results for DA-1726 with specific, credible numerical data (e.g., 68.1% reduction in liver fat, 13.5% weight loss), which supports the realised claims. However, the majority of the narrative is forward-looking, focusing on planned Phase 2 and 2a studies that will not begin until the second half of 2027, making the timeline for any commercial or clinical benefit long-term. The company is incurring rising R&D and G&A expenses, with increasing net losses and declining cash, but this is typical for a clinical-stage biotech. No revenue or profitability metrics are disclosed, as expected for this stage, so the signal cannot be strong_positive. Some language, such as 'positive interim results' and 'advancing' pipeline assets, is optimistic but proportionate to the early-stage data. The claim about preclinical tissue distribution is not quantified, slightly inflating the narrative. Overall, the tone is upbeat but not excessively promotional, and the gap between narrative and evidence is moderate.

Risk flags

• ●MetaVia's cash position declined to $8.8 million as of September 30, 2026, while net losses and operating expenses are rising, increasing the risk of a near-term capital shortfall unless new funding is secured.
• ●The company's most promising clinical data for DA-1726 are based on a very small sample size (n=5 for key endpoints), raising concerns about statistical robustness and the likelihood that results will be replicated in larger trials.
• ●All major clinical milestones, including Phase 2 initiation for DA-1726 and vanoglipel, are at least eight months away, exposing the company to significant execution and development risk over a long timeline with no near-term catalysts.
• ●The company is pre-revenue and entirely dependent on external capital to fund ongoing R&D and operations, making it vulnerable to market conditions and investor sentiment shifts.
• ●Increased R&D and G&A spending, especially on DA-1726, without a corresponding increase in funding or revenue, could further strain liquidity and delay or jeopardize future development.

Bottom line

MetaVia's update combines encouraging early clinical data for DA-1726 with a deteriorating financial position and a long runway before any potential commercial or late-stage clinical value. The company is burning cash, with $8.8 million remaining and net losses accelerating, while all major clinical milestones are at least several quarters away. Interim efficacy signals for DA-1726 are strong but based on a very limited patient cohort, so their predictive value is uncertain. The appointment of an experienced Chief Medical Officer adds credibility to the development plan, but does not address the fundamental funding and execution risks. Investors should focus on MetaVia's ability to secure additional capital and deliver robust data from larger trials. The most important takeaway is that while the science is promising, the path to value realization is long and financially precarious.

Announcement summary

(NASDAQ:MTVA) MetaVia Inc. announced positive interim results from its Phase 1 Part 3B study of DA-1726, a novel oxyntomodulin (OXM) analog and dual GLP-1/glucagon receptor agonist, showing a 68.1% placebo-adjusted reduction in liver fat after approximately 16 weeks, with all five participants with baseline steatosis achieving MRI-PDFF below 5%. The study also demonstrated a 13.5% placebo-adjusted weight loss, significant reductions in adipose tissue, and relative preservation of lean tissue. Additional interim data showed a statistically significant 1.47 mg/dL placebo-adjusted reduction in uric acid after 16 weeks of treatment with DA-1726 (p<0.001). MetaVia plans to initiate a 48-week Phase 2 study in up to 150 subjects with MetALD and ALD, targeted to begin in the second half of 2027. The company appointed Sarah Browne, M.D., as Chief Medical Officer in October 2026 to help lead the next stage of clinical development for DA-1726 and vanoglipel. Preclinical tissue distribution findings for DA-1726 showed the highest exposure in adipose tissue and prolonged tissue retention. The company completed dose titration in the 16-week Phase 1 Part 3 study of DA-1726, with all active patients reaching the highest planned dose levels of 48 mg and 64 mg. Full data from Phase 1 Parts 3A and 3B are expected in the first quarter of 2027. MetaVia is also advancing vanoglipel (DA-1241), a GPR119 agonist, in combination with resmetirom for MASH, with a Phase 2a proof-of-concept study targeted to begin in the first half of 2027. Research and Development (R&D) expenses were approximately $2.6 million for the third quarter ended September 30, 2026, compared to $1.9 million for the same period in 2025, with the $0.7 million increase primarily due to higher direct R&D expenses related to DA-1726, partially offset by $0.2 million in lower indirect consulting expenses. R&D expenses for the nine months ended September 30, 2026, were $8.2 million, compared to $6.6 million for the same period in 2025, with a $1.6 million increase primarily due to $2.0 million in higher direct R&D expenses related to DA-1726, partially offset by $0.2 million in lower indirect consulting expenditures and $0.2 million in lower direct R&D expenses related to vanoglipel. General and Administrative (G&A) expenses were $2.1 million for the third quarter ended September 30, 2026, compared to $1.6 million for the same period in 2025, with the $0.5 million increase primarily due to $0.2 million in higher legal and professional fees, $0.2 million in higher consulting expenditures, and $0.1 million in higher employee compensation and benefits. G&A expenses for the nine months ended September 30, 2026, were $5.9 million, compared to $5.1 million for the same period in 2025, with the $0.8 million increase primarily due to $0.3 million in higher consulting expenditures, $0.2 million in higher legal and professional fees, $0.1 million in higher employee compensation and benefits, and $0.2 million in higher other G&A expenses, mainly related to higher franchise tax expenses. Total operating expenses were $4.7 million for the third quarter ended September 30, 2026, compared to $3.5 million for the same period in 2025, with the $1.2 million increase primarily due to higher R&D and G&A expenses. Total operating expenses for the nine months ended September 30, 2026, were $14.1 million, compared to $11.7 million for the same period in 2025, with the $2.4 million increase primarily due to higher R&D and G&A expenses. Total other income was $0.1 million for the third quarter ended September 30, 2026, unchanged from the same period in 2025. Total other income for the nine months ended September 30, 2026, was $0.3 million, compared to $0.6 million for the same period in 2025, with the $0.3 million decrease primarily due to $0.1 million in lower gain from change in fair value of warrant liabilities and $0.2 million in lower interest income, net. Net loss was $4.6 million, or $0.69 per basic and diluted share, for the third quarter ended September 30, 2026, based on 6,679,250 weighted average shares outstanding, compared to a net loss of $3.4 million, or $1.52 per share, based on 2,219,625 shares for the same period in 2025. Net loss for the nine months ended September 30, 2026, was $13.8 million, or $2.36 per share, based on 5,830,258 shares, compared to $11.0 million, or $6.93 per share, based on 1,592,484 shares for the same period in 2025. Cash and cash equivalents were $8.8 million as of September 30, 2026, compared to $10.3 million as of December 31, 2025.

Disagree with this article?